Неинвазивная визуализация гемопоэтических и опухолевых клеток с использованием молекулярно-биологических методов (экспериментальное обоснование и клинические исследования)
Диссертация
Развитие методов молекулярной визуализации клеток-мишеней в гематологии и онкологии продиктовано требованиями современного уровня развития медицины, ориентированного па применение лечения, специфически влияющего на патогномоничные биологические механизмы, лежащие в основе патологического процесса. Поиск биологических путей и подходов обусловлен необходимостью преодоления ограничений… Читать ещё >
Список литературы
- Mayer-Kuckuk P, Menon LG, Blasberg RG, Bertino JR, Banerjee D Role of reporter gene imaging in molecular and cellular biology. Biol Chem. 2004 May-385(5):353−61. Review.
- Blasberg RG, Gelovani J. Molecular-genetic imaging: a nuclear medicine-based perspective. Mol Imaging. 2002 Jul-l (3):280−300. Review.
- Blasberg RG, Gelovani-Tjuvajev J. In vivo molecular-genetic imaging. J Cell Biochem Suppl. 2002−39:172−83. Review.
- Massoud TF, Gambhir SS Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003 Mar l-17(5):545−80. Review.
- Serganova 1, Blasberg R Reporter gene imaging: potential impact on therapy. Nucl Med Biol. 2005 0ct-32(7):763−80.
- Reddy MP, Reddy P, Lilien DL. F-18 FDG PET imaging in gastrointestinal stromal tumor. Clin Nucl Med. 2003 Aug-28(8):677−9.
- Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging. 2004 Aug-31 (8): 1182−206. Epub 2004 Jul 6. Review
- Ogawa T, Inugami A, Hatazawa J, Kanno I, Murakami M, Yasui N, Mineura K, Uemura K. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-1 lC-methionine. AJNR Am J Neuroradiol. 1996 Feb-17(2):345−53.
- Nunez R, Macapinlac HA, Yeung HW, Akhurst T, Cai S, Osman I, Gonen M, Riedel E, Scher HI, Larson SM Combined 18F-FDG and 1 lC-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002 Jan-43(l):46−55
- Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG J Nucl Med. 2005 Jun-46(6):945−52.
- Chung JK, Lee YJ, Kim SK, Jeong JM, Lee DS, Lee MC. Comparison of 18 °F.fluorodeoxyglucose uptake with glucose transporter-1 expression and proliferation rate in human glioma and non-small-cell lung cancer. Nucl Med Commun. 2004 Jan-25(l):l 1−7.
- Schwarzacher HG, Schnedl W. Position of labelled chromatids in diplochromosomes of endo-reduplicated cells after uptake oftritiated thymidine. Nature. 1966 Jan 1 -209(18): 107−8
- Shields AF, Larson SM, Grunbaum Z, Graham MM. Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med. 1984 Jul-25(7):759−64
- Shields AF, Graham MM, Kozawa SM, Kozell LB, Link JM, Swenson ER, Spence AM, Bassingthwaighte JB, Krohn KA. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds. J Nucl Med. 1992 Apr-33(4):581−4.
- Shields AF, Mankoff D, Graham MM, Zheng M, Kozawa SM, Link JM, Krohn KA. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging. J Nucl Med. 1996 Feb-37(2):290−6.
- Eary JF, Mankoff DA, Spence AM, Berger MS, Olshen A, Link JM, et al. 2-C-l l. thymidine imaging of malignant brain tumors. Cancer Res 1999−59:615−21.
- Zasadny KR, Wahl RL. Standardized uptake values of normal fissues at PET with 2-fluorine-18.-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993−189:847−50.
- Shields AF, Grierson JR, Kozawa SM, Zheng M. Development of labeled thymidine analogs for imaging tumor proliferation. Nucl Med Biol 1996−23:17−22
- Grierson JR, Shields AF. Radiosynthesis of 3'-deoxy-3'-18 °F. fluorothymidine: [18FJFLT for imaging of cellular proliferation in vivo. Nucl Med Biol 2000−27:143−56.
- Choi SJ, Kim JS, Kim JH, Oh SJ, Lee JG, Kim CJ, Ra YS, Yeo JS, Ryu JS, Moon DH18 °F.3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging. 2005 Jun-32(6):653−9. Epub 2005 Feb 15.
- Shields AF, Grierson JR, Dohmen BM, Machulla HJ, Stayanoff JC, Law horn-Crews JM, Obradovich JE, Muzik O, Mangner TJ. Imaging proliferation in vivo with F-18JFLT and positron emission tomography. Nat Med. 1998 Nov-4(l 1): 1334−6
- Sun II, Mangner TJ, Collins JM, Muzik O, Douglas K, Shields AF. Imaging DNA synthesis in vivo with 18F-FMAU and PET. J Nucl Med. 2005 Feb-46(2):292−6.
- Sun H, Sloan A, Mangner TJ, Vaishampayan U, Muzik O, Collins JM, Douglas K, Shields AF Imaging DNA synthesis with 18FJFMAU and positron emission tomography in patients with cancer. Eur J Nucl Med Mol Imaging. 2005 Jan-32(l): 15−22.
- Kao CH, Waki A, Sassaman MB, Jagoda EM, Szajek LP, Ravasi L, Shimoji K, Eckelman WC. Evaluation of 76Br. FBAU 3', 5-dibenzoate as a lipophilic prodrug for brain imaging. Nucl Med Biol. 2002 Jul-29(5):527−35.
- Busch H, Davis JR, Honig GR, Anderson DC, Nair PV, Nyhan WL. The uptake of a variety of amino acids into nuclear proteins of tumors and other tissues. Cancer Res. 1959−19:1030 -1039.
- Isselbacher KJ. Sugar and amino acid transport by cells in culture: differences between normal and malignant cells. N Engl J Med. 1972−286:929 -933.
- Langstrom B, Antoni G, Gullberg P, et al. Synthesis of L- and C-methyl-l lCJmethionine. J Nucl Med. 1987−28:1037−1040.
- Skvortsova TIu, Brodskaia ZL, Rudas MS, Mozhaev SV, Gurchin AF, Medvedev SV. Positron emission tomography in the diagnosis of recurrent growth of brain tumors. Zh Vopr Neirokhir Im N N Burdenko. 2005 Apr-Jun-(2):3−7- discussion 7. Russian.
- Tang BN, Levi vier M, Heureux M, Wikler D, Massager N, Devriendt D, David P, Dumarey N, Corvilain B, Goldman S. (1 l) C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging. 2005 Oct 15
- Toth G, Lengyel Z, Balkay L, Salah MA, Tron L, Toth C. Detection of prostate cancer with 11C-methionine positron emission tomography. J Urol. 2005 Jan-173(l):66−9- discussion 69.
- Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, Jeong JM, Lee DS, Jung HW, Lee MC. Usefulness of 1 lC-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2002 Feb-29(2): 176−82.
- Nakagawa M, Kuwabara Y, Sasaki M, Koga H, Chen T, Kaneko O, Hayashi K, Morioka T, Masuda K1 lC-methionine uptake in cerebrovascular disease: a comparison with 18F-fDG PET and 99mTc-HMPAO SPECT. Ann Nucl Med. 2002 May-16(3):207−11.
- Buonomo C, Mills P, Hilton J, Anderson JH, Wong DF, Dannals RF. Labeled plasma metabolites of L-methyl-hydrogen-3-methionine and L-methyl-carbon-14-methionine in the dog. Am J Physiol Imaging. 1988−3(4):178−81.
- Daemen BJG, Elsinga PH, Paans AMJ, Lemstra W, Konings AWT, Vaalburg W. Suitability of rodent tumor models for experimental PET with L-l-l 1C.- tyrosine and 2-[18F]fluoro-2-deoxy-D-glucose. IntJ RadAppl Instrum B. 1991- 18:503−511.
- Luurtsema G, Medema J, Elsinga PH, Visser GM, Vaalburg W. Robotic synthesis of L-l 1C.-tyrosine. Appl Radiat Isot. 1994−45:821- 828.
- Willemsen AT, van Waarde A, Paans AM, et al. In vivo protein synthesis rate determination in primary or recurrent brain tumors using L-l-l lC.-tyrosine and PET. J Nucl Med. 1995−36:411—419
- Daemen BJG, Elsinga PH, Mooibroek J, et al. PET measurements of hyperthermia- induced suppression of protein synthesis in tumors in relation to effects on tumor growth. J Nucl Med. 1991−32:1587−1592.
- Kersemans V, Cornelissen B, Kersemans K, Bauwens M, Achten E, Dierckx RA, Mertens J, Siegers G. In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an RIM rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT.
- J Nucl Med. 2005 Mar-46(3):532−9
- Langen KJ, Roosen N, Coenen HH, et al. Brain and brain tumor uptake of L-3−123I.iodo-alpha-methyl tyrosine: competition with natural L-amino acids. J Nucl Med. 1991−32:1225−1229
- Langen KJ, Coenen HH, Roosen N, et al. SPECT studies of brain tumors with L-3−1231. iodo-alpha-methyl tyrosine: comparison with PET, 124IMT and first clinical results. J Nucl Med. 1990−31:281−286.
- Jager PL, Franssen EJ, Kool W, et al. Feasibility of tumor imaging using L-3-iodine-123.-iodo-alpha-methyl-tyrosine in extracranial tumors. J Nucl Med. 1998−39:1736 -1743.
- Riemann B, Stogbauer F, Kopka K, et al. Kinetics of 3-(123)lJiodo-l-alphamethyltyrosine transport in rat C6 glioma cells. EurJNuclMed. 1999−26:1274- 1278.
- Jager PL, Plaat BE, Vries de EG, et al. Imaging of soft-tissue tumors using L-3-iodine-123.iodo-alpha-methyl-tyrosine SPECT: comparison with proliferative and mitotic activity, cellularity and vascularity. Clin Cancer Res. 2000−6: 2252−2259.
- Shoup TM, Olson J, Hoffman JM, Votavv J, Eshima D, Eshima L, Camp VM, Stabin M, Votavv D, Goodman MM. Synthesis and evaluation of 18 °F.l-amino-3-fluorocyclobutane-l-carboxylic acid to image brain tumors. J Nucl Med. 1999 Feb-40(2):331−8.
- T. Peng, T.R. Golub, and D.M. Sabatini, «The immunosuppressant rapamycin mimics a starvationlike signal distinct from amino acid and glucose deprivation. Mol Cell Biol., vol.22, pp. 5575−5584, Aug. 2002.
- K.A. Frauwirth, J.L. Riley, M.H. Harris, R.V. Parry, J.C. Rathmell, D.R. Plas, R.L. Elstrom, C.H. June, and C.B. Thompson, „The CD28 signaling pathway regulates glucose metabolism“, Immunity, vol. 16, pp. 769−777, Jun. 2002.
- J.G. Tjuvajev, A. Joshi, J. Callegari, L. Lindsley, R. Joshi, J. Balatoni, R. Finn, S.M. Larson, M.
- Sadelain, and R.G. Blasberg, „A general approach to the non-invasive imaging of transgenes using249cis-linked herpes simplex virus thymidine kinase“, Neoplasia, vol. 1, pp. 315−320, Oct. 1999.
- R. Mayerhofer, K. Araki, and A.A. Szalay, „Monitoring of spatial expression of firefly luciferase in transformed zebra fish“, J Biolumin. Chemilumin., vol. 10, pp. 271−275, Sept.- Oct. 1995.
- J. Bennett, D. Duan, J.F. Engelhardt, and A.M. Maguire, „Real-time, noninvasive in vivo assessment of adeno-associated virus-mediated retinal transduction“, Investigative Ophthalmology & Visual Science, vol. 38, pp. 2857−2863, Dec. 1997.
- A. Rehemtulla, L.D. Stegman, S.J. Cardozo, S. Gupta, D.E. Hall, C.H. Contag and B.D. Ross,"Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging,» Neoplasia, vol.2, pp. 491−495, Nov.-Dec. 2000.
- R. Weissleder, M. Simonova, A. Bogdanova, S. Bredow, W.S. Enochs, and A. Bogdanov, «MR imaging and scintigraphy of gene expression through melanin induction», Radiology, vol. 204, pp. 425−429, Aug. 1997.
- A.Y. Louie, M.M. Huber, E.T. Ahrens, U. Rothbacher, R. Moats, R.E. Jacobs, S.E. Fraser, and T.J. Meade, «In vivo visualization of gene expression using magnetic resonance imaging», Nat. Biotechnol., vol. 18, pp. 321−325, Mar. 2000.
- MacGregor GR, Mogg AE, Burke JF, Caskey CT. Histochemical staining of clonal mammalian cell lines expressing E. coli beta galactosidase indicates heterogeneous expression of the bacterial gene. Somat Cell Mol Genet. 1987 May-13(3):253−65.
- Dachs GU, Tupper J, Tozer GM. From bench to bedside for gene-directed enzyme prodrug therapy250of cancer. Anticancer Drugs. 2005 Apr- 16(4):349−59. Review.
- Doubrovin M, Balatoni J, Finn R, Sgouros G and Tjuvajev JG Radio-gene therapy of gliomas with HSVl-tk gene and high dose 1311JFIAU. [Abstract # 979. Proceedings of the American Association for Cancer Research, 1999- 40: 147.
- Re GG, Hazen-Martin DJ, Sens DA, Garvin AJ. Nephroblastoma (Wilms* tumor): a model system of aberrant renal development. Semin Diagn Pathol. 1994 May-l l (2):126−35. Review
- Harris SL, Levine AJ The p53 pathway: positive and negative feedback loops. Oncogene. 2005 Apr 18−24(17):2899−908. Review.
- Jascur T, Gilman J, Mustelin T. Involvement of phosphatidylinositol 3-kinase in NFAT activation in T cells. J Biol Chem. 1997 May 30−272(22): 14 483−8. TKP
- Woodrow M, Clipstone NA, Cantrell D p21ras and calcineurin synergize to regulate the nuclear factor of activated T cells. J Exp Med. 1993 Nov 1- 178(5): 1517−22.
- Tanguay RM. Transcriptional activation of heat-shock genes in eukaryotes. Biochem Cell Biol. 1988 Jun-66(6):584−93. Review.
- Karin M. Signal transduction and gene control. Curr Opin Cell Biol. 1991 Jun-3(3):467−73. Review
- HIavaty J, Portsmouth D, Stracke A, Salmons B, Gunzburg WH, Renner M. Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral vectors. Virology. 2004 Dec5−330(1):351−60.
- Stevenson M, Volsky DJ Activated v-myc and v-ras oncogenes do not transform normal human lymphocytes. Mol Cell Biol. 1986 Oct-6(10):3410−7.
- Ernstsson S, Pierrou S, Hulander M, Cederberg A, Hellqvist M, Carlsson P, Enerback S Characterization of the human forkhead gene FREAC-4. Evidence for regulation by Wilms' tumor suppressor gene (WT-1) and p53. J Biol Chem. 1996 Aug 30−271(35):21 094−9.
- Wang Y, Farmer G, Soussi T, Prives C Xenopus laevis p53 protein: sequence-specific DNA binding, transcriptional regulation and oligomerization are evolutionarily conserved. Oncogene.1995 Feb 16−10(4):779−84.
- Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996 May 1- 10(9): 1054−72. Review.
- Hooijberg E, Bakker AQ, Ruizendaal JJ, Spits H. NFAT-controlled expression of GFP permits visualization and isolation of antigen-stimulated primary human T cells. Blood. 2000 Jul 15−96(2):459−66.
- Brown JM. Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies. Mol Med Today. 2000 Apr-6(4): 157−62. Review.
- Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol.1996 Sep-16(9):4604−13.
- Flynn GC, Chappell TG, Rothman JE. Peptide binding and release by proteins implicated as catalysts of protein assembly. Science. 1989 Jul 28−245(4916):385−90.
- Stephanou A, Isenberg DA, Nakajima K, Latchman DS. Signal transducer and activator of transcription-1 and heat shock factor-1 interact and activate the transcription of the Hsp-70 and Hsp-90beta gene promoters. J Biol Chem. 1999 Jan 15−274(3): 1723−8
- Smith DF, Whitesell L, Nair SC, Chen S, Prapapanich V, Rimerman RA Progesterone receptor252structure and function altered by geldanamycin, an hsp90-binding agent. Mol Cell Biol. 1995 Dec-15(12):6804−12
- P. Ray P, A.M. Wu, S.S. Gambhir, «Optical bioluminescence and positron emission tomography imaging of a novel fusion reporter gene in tumor xenografts of living mice», Cancer Res., vol. 63, pp. 1160−1165, Mar. 2003.
- S. Hasegawa, M. Yang, T. Chishima, Y. Miyagi, H. Shimada, A.R. Moossa, and R.M. Hoffman, «In vivo tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis», Cancer Gene Therapy, vol. 7, pp. 1336−1334, Oct. 2000.
- R.M. Hoffman, «Visualization of GFP-expressing tumors and metastasis in vivo», Biotechniques, vol. 30, pp. 1016−1022, May 2001.
- S. Pelletier, «Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA», Nature, vol. 334, pp. 320−325, 1988.
- A.B. Sachs, P. Sarnow, and M.W. Hentze, «Starting at the Beginning, Middle, and End Translation Initiation in Eukaryotes», Cell, vol. 89, pp. 831−838, Jun. 1997.
- B.E. Rogers, K.R. Zinn, and D.J. Buchsbaum, «Gene transfer strategies for improvingradiolabeled peptide imaging and therapy», QJNucl. Med., vol.44, pp. 208−223, Sept. 2000.
- V.A. Kolb, E.V. Makeyev, and A.S. Spirin, «Co-translational folding of an eukaryotic multidomain protein in a prokaryotic translation system,» J Biol Chcm., vol. 275, pp. 16 597−601, Jun. 2000.
- J.F. Thompson, L.S. Hayes, D.B. Lloyd, «Modulation of firefly luciferase stability and impact on studies of gene regulation», Gene, vol. 103, pp. 171−177, Jul. 1991.
- R.N. Day, M. Kawecki, and D. Berry, «Dual function reporter protein for analysis of gene expression in living cells», Biotechnology, vol.25, pp. 852−854, Nov. 1998.
- Deshmukh A, Scott JA, Palmer EL, Hochberg FH, Gruber M, Fischman AJ Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma. Clin Nucl Med. 1996 Sep-21(9):720−5.
- Finlay JL, Uteg R, Giese WL. Brain tumors in children. II. Advances in neurosurgery and radiation oncology. Am J Pediatr Hematol Oncol. 1987 Fall-9(3):256−63. Review, clin vis
- Gossmann A, Eich HT, Engert A, Josting A, Muller RP, Diehl V, Lackner KJ. CT and MR imaging in Hodgkin’s disease—present and future. Eur J Haematol Suppl. 2005 Jul-(66):83−9. Review.
- Bradbury M, Hricak II Molecular MR imaging in oncology. Magn Reson Imaging Clin N Am. 2005 May-13(2):225−40. Review.
- Schaefer-Prokop C, Prokop M. New imaging techniques in the treatment guidelines for lung cancer. Eur Respir J Suppl. 2002 Feb-35:71s-83s. Review.
- Macapinlac HA. FDG PET and PET/CT imaging in lymphoma and melanoma. Cancer J. 2004
- Jul-Aug- 10(4):262−70. Review. PET-CT
- Hudson MM, Krasin MJ, Kaste SC. PET imaging in pediatric Hodgkin’s lymphoma. Pediatr
- Radiol. 2004 Mar-34(3): 190−8. Epub 2004 Jan 27. Review.
- Gijtenbeek JM, Wesseling P, Maass C, Burgers L, van der Laak JA Three-dimensional reconstruction of tumor microvasculature: Simultaneous visualization of multiple components in paraffin-embedded tissue. Angiogenesis. 2005 Nov 19-: 1−9
- Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005 Aug-19(4):611−27, v. Review.
- Mogul MJ. Unrelated cord blood transplantation vs matched unrelated donor bone marrow transplantation: the risks and benefits of each choice.
- Bone Marrow Transplant. 2000 May-25 Suppl 2: S58−60. Review, bmt opt for pts
- X. Wang, M. Rosol, S. Ge, D. Peterson, G. McNamara, H. Pollack, D.B. Kohn, M.D. Nelson, and G.M. Crooks, «Dynamic tracking of human hematopoietic stem cell engraftment using in vivo bioluminescence imaging», Blood, vol. 102, pp. 3478−82, Nov. 2003.
- J.M. Hill, A.J. Dick, V.K. Raman, R.B. Thompson, Z.X. Yu, K.A. Hinds, B.S. Pessanha, M.A.255
- Guttman, T.R. Varney B.J. Martin, C.E. Dunbar, E.R. McVeigh, and R.J. Lederman, «Serial cardiac magnetic resonance imaging of injected mesenchymal stem cells», Circulation, vol. 108, pp. 1009−1014, Aug. 2003.
- C. Stamm, B. Westphal, H.D. Kleine, M. Petzsch, C. Kittner, H. Klinge, C. Schumichen, C.A. Nienaber, M. Freund, and G. Steinhoff, «Autologous bonc-marrow stem-cell transplantation for myocardial infarction», Lancet, vol. 361, pp. 45−46, Jan. 2003.
- O’Reilly RJ, Small TN, Papadopoulos E, Lucas K, Lacerda J, Koulova L., Biology and adoptive cell therapy of Epstein-Barr virus-associated lymphoproliferative disorders in recipients of marrow allografts. Immunol Rev. 1997 Jun- 157:195−216. Review.
- Heslop HE. Biology and treatment of epstein-barr virus-associated non-hodgkin lymphomas. Hematology (Am Soc Hematol Educ Program). 2005-:260−6.
- Lucas KG, Small TN, Heller G, Dupont B, O’Reilly RJ Lucas The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood. 1996 Mar 15−87(6):2594−603.,
- Zatz, M.M. and Lance, E.M. The distribution of chromium 51-labelled lymphoid cells in the mouse. 1970 Cell. Immunol. 1, 3.
- Gobuty AH, Robinson RG, Barth RF. Organ distribution of 99mTc- and 51Cr-labeled autologous peripheral blood lymphocytes in rabbits. J Nucl Med. 1977 Feb- 18(2): 141−6.
- Papierniak CK, Bourey RE, Kretschmer RR, Gotoff SP, Colombetti LG. Technetium-99m labeling of human monocytes for chemotactic studies. J Nucl Med. 1976 Nov-17(l l):988−92.
- Korf J, Veenma-van der Duin L, Brinkman-Medema R, Niemarkt A, de Leij LF. Divalent cobalt as a label to study lymphocyte distribution using PET and SPECT. J Nucl Med. 1998 May-39(5):836−41.
- Korf J, Veenma-van der Duin L, Brinkman-Medema R, Niemarkt A, de Leij LF (1998) Divalent cobalt as a label to sudy lymphocytes distribution using PET and SPECT. J Nuc Med 39(5), 836−841.
- Wagstaff J, Gibson C, Thatcher N, Ford WL, Sharma H, Benson W, Crowther D (1981) A method for following human lymphocyte traffic using indium-Ill oxine labeling. Clin Exp Immunol 43(3), 435−42.
- Constantin G, Laudanna C, Butcher EC. Novel method for following lymphocyte traffic in mice using 3H. glycerol labeling. J Immunol Methods. 1997 Apr 1 l-203(l):35−44.
- Mandell RB, Mandell LZ, Link CJ Jr. (1999) Radioisotope concentrator gene therapy using the sodium/iodide symporter gene. Cancer Res- 59(3):661−8.
- Atkins RC, Ford WL. Early cellular events in a systemic graft-vs.-host reaction. I. The migration of responding and nonresponding donor lymphocytes. J Exp Med. 1975 Mar l-141(3):664−80.
- Rose ML, Parrott DM, Bruce RG.I. Effect of Trichinella spiralis infection on the migration of mesenteric lymphoblasts and mesenteric T Iymphoblasts in syngeneic mice. Immunology. 1976 Nov-31(5):723−30.
- Ettinghausen SE, Rosenberg SA. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2. Cancer Res. 1986 Jun-46(6):2784−92.
- Schelper RL, Adrian EK Jr. Non-specific esterase activity in rcactive cells in injured nervous tissue labeled with 3H-thymidine or 125iododeoxyuridine injected before injury. J Comp Neurol. 1980 Dec 15- 194(4):829−44.
- Schelper RL, Adrian EK Jr. Monocytes become macrophages- they do not become microglia: a light and electron microscopic autoradiographic study using 125-iododeoxyuridine. J Neuropathol Exp Neurol. 1986 Jan-45(l): 1−19.
- Tjuvajev JG, Macapinlac HA, Daghighian F, Scott AM, Ginos JZ, Finn RD, Kothari P, Desai R, Zhang J, Beattie B, et al. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine. JNucl Med. 1994 Sep-35(9):1407−17.
- Bunn PA Jr, Carrasquillo JA, Keenan AM, Schroff RW, Foon KA, Hsu SM, Gazdar AF, Reynolds JC, Perentesis P, Larson SM. Imaging of T-cell lymphoma by radiolabeled monoclonal antibody. Lancet. 1984 Nov 24−2(8413): 1219−21.
- Signore A, Chianelli M, Annovazzi A, Rossi M, Maiuri L, Greco M, Ronga G, Britton KE, Picarelli A (2000) Imaging active limphocytic infiltration in celiac disease with iodine-123-interleukin-2 and the response to diet. EurJNuc Med 27(12), 1754−9.
- Yeh TC, Zhang W, Ildstad ST, Ho C. In vivo dynamic MRI tracking of rat T-cells labeled with superparamagnetic iron-oxide particles. Magn Reson Med 1995 Feb-33(2):200−8.
- Dodd SJ, Williams M, Suhan JP, Williams DS, Koretsky AP, Ho C. Biophys J 1999 Jan-76(l
- Pt 1): 103 176. Dodd J Immunol Methods 2001 Oct l-256(l-2):89−105
- Hardy J, Edingcr M, Bachmann MH, Negrin RS, Fathman CG, Contag CH (2001) Bioluminescence imaging of lymphocyte trafficking in vivo. Exp Hematol 29, 1353−60.
- Collett MS, Erikson RL Protein kinase activity associated with the avian sarcoma virus src gene product. Proc Natl Acad Sei USA. 1978 Apr-75(4):2021−4.
- Pastan I, Willingham M. Cellular transformation and the 'morphologic phenotype' of transformed cells. Nature. 1978 Aug 17−274(5672):645−50. Review.
- Honma Y, Okabe-Kado J, Hozumi M, Uehara Y, Mizuno S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res. 1989 Jan 15−49(2):331−4.
- Cortes J, Kantarjian H. New targeted approaches in chronic myeloid leukemia. J Clin Oncol. 2005 Sep 10−23(26):6316−24. Review.
- Schindler T., Bommann W., Pellicena P., Miller W.T., Clarkson B. and Kuriyan J. (2000) Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Scicnce, 289:1938−1942.
- Sawyers C.L. (1999) Chronic myeloid leukemia. N Engl J Med, 340:1330−1340.
- Dinulescu DM, Wood LJ, Shen L, Loriaux M, Corless CL, Gross AW, Ren R, Deininger MW, Druker BJ. c-CBL is not required for leukemia induction by Bcr-Abl in mice. Oncogene. 2003 Dec 4−22(55):8852−60,
- Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J. and Lydon N.B. (1996) Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med, 2:561−566.
- Moasser M. M., Srethapakdi M., Sachar K. S., Kraker A. J., Rosen N. Inhibition of Src kinases by a selective tyrosine kinase inhibitor causes mitotic arrest. Cancer Res., 59: 6145−6152, 1999.
- Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20−305(5687):1163−7. Epub 2004 Jul 29.
- Katzenellenbogen BS, Miller MA, Eckert RL, Sudo K. Antiestrogen pharmacology and mechanism of action. J Steroid Biochem. 1983 Jul- 19(1 A):59−68.
- Ben-David I, Rozen Y, Ortu G, et al. Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: 1 lCJAcryloyl chloride. Appl Radiat Isot 2003- 58:209−17.
- Shah NT, Miller VA. Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program. Clin Lung Cancer. 2003 Nov-5(3): 182−6.
- Sordella R, Bell DW, Haber DA, Settleman J Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science. 2004 Aug 20−305(5687):1163−7. Epub 2004 Jul 29.
- Ohe Y Chemoradiotherapy for lung canccr: current status and perspectives. Int J Clin Oncol. 2004 Dec-9(6):435−43. Review.
- Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R. and
- Talpaz M. (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 344:1038−1042.
- Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R.L., Rao N. and Sawyers C.L. (2001) Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification.1. Science, 293:876−880.
- Balter M. Gene therapy on trial. Science. 2000 May 12−288(5468):951−7. exp
- Habib NA, Hodgson HJ, Lemoine N, Pignatelli M A phase I/I I study of hepatic artery infusion with wtp53-CMV-Ad in metastatic malignant liver tumours. Hum Gene Ther. 1999 Aug 10−10(12):2019−34.
- Richards CA, Austin EA, Huber BE Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy.
- Kennedy PG, Steiner I. The use of herpes simplex virus vectors for gene therapy in neurological diseases. Q J Med. 1993 Nov-86(l l):697−702. Review.
- Muller SR, Sullivan PD, Clegg DO, Feinstein SC. Efficient transfection and expression of heterologous genes in PC 12 cells. DNA Cell Biol. 1990 Apr-9(3):221−9.
- Smitt PS, Driesse M, Wolbers J, Kros M, Avezaat C Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. Mol Ther. 2003 Jun-7(6):851−8.
- Kitayama S, Kumagai K, Morita K, Dohi T Identification and functional characterization of the novel isoforms of bovine norepinephrine transporter produced by alternative splicing. Brain Res. 2002 May 3−934(2): 152−6.
- Riviere I, Brose K, and Mulligan RC. (1995) Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Nail Acad Sci USA 92, 6733-?.
- J. Che, Doubrovin M, Blasberg RG. Imaging hNIS. Mol. Imaging. 2005 4(2): 128−36.
- Qiao J, Doubrovin M. Sauter BV, Huang Y, Guo ZS, Balatoni J, Akhurst T, Blasberg RG, Tjuvajev JG, Chen SH, Woo SL. Tumor-specific transcriptional targeting of suicide gene therapy Gene Ther. 2002 Feb-9(3):168−75.
- Kern S. E/. KinzlerK.W., Bruskin A., Jarosz D., Friedman P., Prives C., and Vogelstein B. Science 1991 252, 1708−11.
- Early PW, Davis MM, Kaback DB, Davidson N, Hood L Immunoglobulin heavy chain organization in mice: analysis of myeloma genomic code containing variable and alpha concstant regions Proc Natl Acad Sci 1979 76:857−61.
- Keller C, Hyrien O, Knippers R, Krude T Site-specific and temporally controlled initiation of DNA replication in a human cell-free system. Nucleic Acids Res. 2002 May 15−30(10):2114−23.